Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Nordea in connection with Karo Intressenter’s public offer for Karo Pharma
Mandate

Vinge advised Nordea in connection with Karo Intressenter’s public offer for Karo Pharma

September 19, 2022 Capital Markets and Public M&A Life Sciences & Health

Vinge has advised Nordea Bank Abp, filial i Sverige, Corporate Finance in connection with the rendering of a fairness opinion regarding Karo Intressenter’s public offer to the shareholders of Karo Pharma AB.

Vinges team consisted through public M&A and capital markets partner Erik Sjöman.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026

Vinge has advised Resurs in connection with its strategic partnership with Kustom

 Vinge has advised Resurs in connection with its strategic partnership with Kustom (formerly Klarna Checkout), a fast-growing player in the digital commerce sector. The partnership enables Resurs to accelerate its strategic development by offering a check-out solution to its merchants, built on Kustom’s market-leading infrastructure.
March 25, 2026